SALT LAKE CITY & SAN FRANCISCO--(BUSINESS WIRE)--Culmination Bio, a new Intermountain Health Company, and Cofactor Genomics, a predictive diagnostic immunotherapy company, today announced a ...

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, ...

Patent Represents Major Step Towards Bridging the Precision Medicine Gap Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right ...

SAN FRANCISCO--(BUSINESS WIRE)--Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in non-small cell lung ...

Respective Leaders in Cancer Care and RNA Collaborate to Leverage Predictive Immune Modeling for Improved Clinical Decision-Making ...

Researchers determined the Foxp3 protein is actually a cofactor, hijacking DNA-binding proteins responding to the immunological environment of the T cell. Based on the type of response needed, ...

Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism classifier as a predictive ...

SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, leading developer of advanced RNA analysis tools, announced today that they have entered into an agreement with the National Cancer ...

In a cruel twist, the bacterium Clostridioides difficile (C. diff) makes us bleed and then uses our blood to defend itself against us. Vanderbilt University Medical Center scientists have identified a ...

Yongqiang Feng, PhD, St. Jude Department of Immunology, investigated the role Foxp3 plays in regulatory T cell function, demonstrating that the protein likely acts as a transcription cofactor, ...